Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

BridgeBio Pharma, Inc. - Common Stock (NQ:BBIO)

65.06 -1.16 (-1.75%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 13, 2025 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	1,779,147
Open	65.13
Bid (Size)	61.70 (200)
Ask (Size)	67.49 (200)
Prev. Close	66.22
Today's Range	64.95 - 67.28
52wk Range	21.72 - 69.48
Shares Outstanding	160,500,999
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Healthcare Sector Navigates Turbulent Waters: Innovation Surges Amidst Political Headwinds

November 10, 2025

New York, NY – November 10, 2025 – The S&P 500 Healthcare sector presented a mixed picture today, with the broader index showing a modest uptick while significant segments, particularly health insurers...

Via MarketMinute

Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations

November 08, 2025

From BridgeBio Pharma, Inc.

Via GlobeNewswire

Performance

YTD	+130.7%	+130.7%
1 Month	+16.3%	+16.3%
3 Month	+29.1%	+29.1%
6 Month	+93.3%	+93.3%
1 Year	+164.3%	+164.3%

More News

Biotech Sector Soars: Promising Drug Trials Ignite Investor Confidence and Spark Market Rally

November 07, 2025

Via MarketMinute

BridgeBio to Participate in November Investor Conferences

November 04, 2025

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio to Present Data from the Overall ATTR-CM Variant and V142I (V122I) Populations from ATTRibute-CM at the AHA Scientific Sessions 2025

November 03, 2025

From BridgeBio Pharma, Inc.

Via GlobeNewswire

Alnylam Stock Has Already Doubled In 2025. Why It Could Rocket Again On Earnings. ↗

October 30, 2025

Via Investor's Business Daily

BridgeBio Pharma (NASDAQ:BBIO) Q3 2025 Revenue Beat Overshadowed by Widened Loss ↗

October 29, 2025

Via Chartmill

Earnings Scheduled For October 29, 2025 ↗

October 29, 2025

Via Benzinga

Earnings Outlook For BridgeBio Pharma ↗

October 28, 2025

Via Benzinga

BridgeBio Reports Third Quarter 2025 Financial Results and Business Updates

October 29, 2025

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio's Investigation Drug Outperforms Standard Therapy In Rare Calcium Disorder ↗

October 29, 2025

Via Benzinga

BridgeBio Shares Second Positive Late-Stage Study Result In A Week – Calcium Disorder Drug Trial Yields Positive Results ↗

October 29, 2025

Via Stocktwits

BridgeBio Pharma Lines Up Another 'Domino' As It Nears A Record High ↗

October 29, 2025

Via Investor's Business Daily

BridgeBio Reports Positive Phase 3 Topline Results for Encaleret in Patients with Autosomal Dominant Hypocalcemia Type 1

October 29, 2025

From BridgeBio Pharma, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

October 28, 2025

Via Benzinga

BridgeBio to Report Phase 3 Results for Encaleret in ADH1 CALIBRATE Study on Wednesday, October 29th

October 28, 2025

From BridgeBio Pharma, Inc.

Via GlobeNewswire

Janus Henderson, Avidity Biosciences, BridgeBio Pharma And Other Big Stocks Moving Higher On Monday ↗

October 27, 2025

Via Benzinga

BBIO Stock Soars After Experimental Drug Shows Improvement In Inherited Muscle Disorder In Late-stage Trial ↗

October 27, 2025

Via Stocktwits

BridgeBio Reports Positive Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study

October 27, 2025

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio to Report Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study, along with Third Quarter 2025 Financial Results Next Week

October 24, 2025

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

October 03, 2025

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio's Acoramidis Cuts Risk Within Weeks In Rare Heart Condition ↗

September 29, 2025

Via Benzinga

BridgeBio, Up 80% This Year, Just Unveiled Promising News For Its Pfizer Rival ↗

September 28, 2025

Via Investor's Business Daily

Acoramidis Begins to Reduce Cumulative Cardiovascular Outcomes Within the First Month of Treatment in Patients with ATTR-CM

September 28, 2025

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio Pharma Inc (NASDAQ:BBIO) Shows Strong Technical Setup for Potential Breakout ↗

September 22, 2025

Via Chartmill

Frequently Asked Questions

Is BridgeBio Pharma, Inc. - Common Stock publicly traded?

Yes, BridgeBio Pharma, Inc. - Common Stock is publicly traded.

What exchange does BridgeBio Pharma, Inc. - Common Stock trade on?

BridgeBio Pharma, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for BridgeBio Pharma, Inc. - Common Stock?

The ticker symbol for BridgeBio Pharma, Inc. - Common Stock is BBIO on the Nasdaq Stock Market

What is the current price of BridgeBio Pharma, Inc. - Common Stock?

The current price of BridgeBio Pharma, Inc. - Common Stock is 65.06

When was BridgeBio Pharma, Inc. - Common Stock last traded?

The last trade of BridgeBio Pharma, Inc. - Common Stock was at 11/13/25 04:00 PM ET

What is the market capitalization of BridgeBio Pharma, Inc. - Common Stock?

The market capitalization of BridgeBio Pharma, Inc. - Common Stock is 10.44B

How many shares of BridgeBio Pharma, Inc. - Common Stock are outstanding?

BridgeBio Pharma, Inc. - Common Stock has 10B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.